Drugs / anti-PD1 antibody-activated TILs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03903887 | Feb → Dec 2019 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-PD1 antibody-activated TILs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03903887 ↗ |
| Action | Activate | “anti-PD1 antibody-activated TILs” NCT03903887 ↗ |
| Modality | Cell therapy | “Then, autologous TILs (0.1-1\*10\^10 cells) were transferred to participants via intravenous infusion.” NCT03903887 ↗ |
| Route | Intravenous | “transferred to participants via intravenous infusion” NCT03903887 ↗ |